|
시장보고서
상품코드
2055191
심근허혈 시장 : 질환 유형별, 약제 클래스별, 투여 경로별, 약제 유형별, 최종사용자별, 유통 채널별, 지역별Myocardial Ischemia Market, By Disease Type, By Drug Class, By Route of Administration,By Drug Type, By End User, By Distribution Channel, By Geography |
||||||
심근허혈 시장은 2026년에 51억 달러로 추정되며, 2033년까지 87억 4,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 8.0%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 51억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 8.00% | 2033년 시장 규모 예측 : | 87억 4,000만 달러 |
세계 심근 허혈 시장은 심혈관 치료 분야의 중요한 부문으로, 전 세계 사망 및 질병의 주요 원인 중 하나를 다루고 있습니다. 심근 허혈은 관상동맥의 폐색이나 경련으로 인한 심근 혈류 감소가 특징이며, 전 세계 수백만 명의 환자에게 영향을 미치고 있으며, 안정형 협심증에서 급성 관상동맥 증후군에 이르기까지 광범위한 병태를 포함합니다. 이 시장에는 항혈소판제, 베타 차단제, ACE 억제제, 스타틴 등의 약물 치료는 물론, 경피적 관상동맥 중재술(PCI)이나 관상동맥 우회술(CABG)과 같은 고도의 중재술 기법을 포함한 다양한 치료법이 포함되어 있습니다.
당뇨병, 고혈압, 비만, 운동 부족과 같은 심혈관 질환의 위험 요인 유병률이 증가하는 데다 전 세계적으로 고령화가 진행됨에 따라, 해당 환자층은 크게 확대되고 있습니다. 또한, 진단법, 약물 전달 시스템, 최소 침습 수술 기술 분야의 기술적 진보가 치료 패러다임에 혁명을 일으키며 시장 성장을 주도하고 있습니다. 또한, 이 시장은 환자의 예후를 개선하면서 의료 비용을 절감하는 새로운 치료 표적, 맞춤형 의료 접근법 및 병용 요법에 초점을 맞춘 활발한 연구 개발 활동의 혜택을 받고 있습니다.
시장 역학
세계 심근 허혈 시장은 성장 궤도를 지속적으로 형성하고 있는 몇 가지 주요 촉진요인에 의해 주도되고 있습니다. 주요 성장 요인은 전 세계적으로 심혈관 질환의 부담이 증가하고 있다는 점이며, 심근 허혈은 심장 관련 입원 및 의료비의 상당 부분을 차지하고 있습니다. 특히 개발도상국에서 당뇨병, 고혈압, 이상지질혈증, 흡연 등 생활습관과 관련된 위험 요인의 유병률이 높아지고 있어 환자층이 크게 확대되고 있습니다.
또한, 영상 진단, 바이오마커 검출 및 치료적 개입 분야의 기술 혁신으로 인해 조기 발견과 치료 효과가 향상되어 시장 확산을 촉진하고 있습니다. 서방형 제제 및 병용 요법을 포함한 새로운 약제 제제의 개발로 인해, 환자의 복약 순응도와 임상 결과가 개선되었습니다. 그러나 시장은 성장세를 저해할 수 있는 뚜렷한 제약에 직면해 있습니다.
고도의 중재적 시술이나 만성 질환의 약물 치료에 수반되는 고액의 치료비는 특히 의료 자원이 제한적인 의료 시스템에서 큰 장벽이 되고 있습니다. 의료기기 승인 및 의약품 개발을 규제하는 엄격한 체계는 승인까지의 기간을 길게 만들고, 개발 비용을 크게 증가시키고 있습니다. 게다가 전문적인 지식과 인프라가 필요한 심혈관 의료의 복잡성은 의료 서비스가 충분히 제공되지 않는 지역에서 시장 진출을 제한하고 있습니다. 블록버스터급 심혈관 의약품의 특허 만료로 인해 제네릭 의약품과의 경쟁이 심화되면서, 기존 기업들의 수익원에 압박을 가하고 있습니다.
이러한 과제가 존재하지만, 경제 성장과 의료 인프라 구축이 진행되고 있는 신흥 시장에는 큰 기회가 존재합니다. 예방 심장학 및 위험군 분류에 대한 관심이 높아지고 있는 것은 진단 및 모니터링 기술에 있어 좋은 기회가 됩니다. 디지털 헬스 플랫폼, 원격의료, 인공지능(AI) 용도의 발전은 환자 관리 개선 및 치료 최적화로 이어질 가능성을 내포하고 있습니다.
또한, 유전자 프로파일링 및 바이오마커 식별에 기반한 맞춤형 의료와 정밀의료에 대한 관심이 높아지고 있는 점은 시장 확대를 위한 유망한 신성장 분야로 부상하고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 심근 허혈 시장의 주요 기업 프로파일을 분석했습니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 심근 허혈 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 심근 허혈 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 심근허혈 시장 : 질환 유형별, 2021년-2033년
제5장 세계의 심근허혈 시장 : 약제 클래스별, 2021년-2033년
제6장 세계의 심근허혈 시장 : 투여 경로별, 2021년-2033년
제7장 세계의 심근허혈 시장 : 약제 유형별, 2021년-2033년
제8장 세계의 심근허혈 시장 : 최종사용자별, 2021년-2033년
제9장 세계의 심근허혈 시장 : 유통 채널별, 2021년-2033년
제10장 세계의 심근허혈 시장 : 지역별, 2021년-2033년
제11장 경쟁 구도
제12장 애널리스트의 제안
제13장 참고 문헌 및 조사 방법
LSH 26.06.22Myocardial Ischemia Market is estimated to be valued at USD 5.10 Bn in 2026 and is expected to reach USD 8.74 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.10 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.00% | 2033 Value Projection: | USD 8.74 Bn |
The global myocardial ischemia market represents a critical segment within the cardiovascular therapeutics landscape, addressing one of the leading causes of mortality and morbidity worldwide. Myocardial ischemia, characterized by reduced blood flow to the heart muscle due to coronary artery obstruction or spasm, affects millions of patients globally and encompasses conditions ranging from stable angina to acute coronary syndromes. The market encompasses diverse therapeutic interventions including pharmacological treatments such as antiplatelet agents, beta-blockers, ACE inhibitors, and statins, alongside advanced interventional procedures like percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).
The increasing prevalence of cardiovascular risk factors including diabetes, hypertension, obesity, and sedentary lifestyles, coupled with an aging global population, has significantly expanded the addressable patient population. Furthermore, technological advancements in diagnostic modalities, drug delivery systems, and minimally invasive surgical techniques have revolutionized treatment paradigms, driving market growth. The market also benefits from robust research and development activities focused on novel therapeutic targets, personalized medicine approaches, and combination therapies that improve patient outcomes while reducing healthcare costs.
Market Dynamics
The global myocardial ischemia market is propelled by several key drivers that continue to shape its trajectory. The primary growth driver stems from the escalating global burden of cardiovascular diseases, with myocardial ischemia representing a significant portion of cardiac-related hospitalizations and healthcare expenditures. Rising prevalence of lifestyle-associated risk factors including diabetes mellitus, hypertension, dyslipidemia, and smoking, particularly in developing economies, has expanded the patient pool substantially.
Additionally, technological innovations in diagnostic imaging, biomarker detection, and therapeutic interventions have enhanced early detection and treatment efficacy, driving market adoption. The development of novel drug formulations, including extended-release medications and combination therapies, has improved patient compliance and clinical outcomes. However, the market faces notable restraints that could impede growth momentum.
High treatment costs associated with advanced interventional procedures and chronic medication regimens pose significant barriers, particularly in resource-constrained healthcare systems. Stringent regulatory frameworks governing medical device approvals and pharmaceutical development create lengthy approval timelines and substantial development costs. Additionally, the complexity of cardiovascular care requiring specialized expertise and infrastructure limits market penetration in underserved regions. Patent expirations of blockbuster cardiovascular medications have intensified generic competition, pressuring revenue streams for established players.
Despite these challenges, substantial opportunities exist within emerging markets experiencing economic growth and healthcare infrastructure development. The increasing focus on preventive cardiology and risk stratification presents opportunities for diagnostic and monitoring technologies. Advances in digital health platforms, telemedicine, and artificial intelligence applications offer potential for improving patient management and treatment optimization.
Furthermore, the growing emphasis on personalized medicine and precision therapeutics based on genetic profiling and biomarker identification represents a promising frontier for market expansion.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myocardial ischemia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, AstraZeneca PLC, Bayer AG, Novartis AG, Merck and Co Inc, Bristol-Myers Squibb Company, Sanofi SA, Daiichi Sankyo Company Limited, Gilead Sciences Inc, Johnson and Johnson, Amgen Inc, Boehringer Ingelheim, Mylan NV, Teva Pharmaceutical Industries Ltd, and GlaxoSmithKline PLC
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global myocardial ischemia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myocardial ischemia market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Stable Angina
- Unstable Angina
- Silent Myocardial Ischemia
- Vasospastic (Prinzmetal) Angina
- Microvascular Ischemia
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Anti-Anginal Agents (e.g., nitroglycerin, isosorbide mononitrate)
- Antiplatelet Agents (e.g., aspirin, clopidogrel, ticagrelor)
- Anticoagulants (e.g., heparin, enoxaparin, apixaban)
- Beta-Blockers (e.g., metoprolol, atenolol, carvedilol)
- ACE Inhibitors (e.g., ramipril, lisinopril, enalapril)
- Angiotensin II Receptor Blockers (e.g., losartan, valsartan, telmisartan)
- Calcium Channel Blockers (e.g., amlodipine, diltiazem, verapamil)
- Nitrates (e.g., nitroglycerin spray, isosorbide dinitrate)
- Statins (e.g., atorvastatin, rosuvastatin, simvastatin)
- Late Sodium Current Inhibitors/Ranolazine (e.g., ranolazine)
- Thrombolytics (e.g., alteplase, tenecteplase, streptokinase)
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
- Branded
- Generic
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Cardiac Specialty Clinics
- Diagnostic Centers
- Ambulatory Surgical Centers
- Research and Academic Institutes
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- AstraZeneca PLC
- Bayer AG
- Novartis AG
- Merck and Co Inc
- Bristol-Myers Squibb Company
- Sanofi SA
- Daiichi Sankyo Company Limited
- Gilead Sciences Inc
- Johnson and Johnson
- Amgen Inc
- Boehringer Ingelheim
- Mylan NV
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline PLC
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Myocardial Ischemia Market, By Disease Type
- Global Myocardial Ischemia Market, By Drug Class
- Global Myocardial Ischemia Market, By Route of Administration
- Global Myocardial Ischemia Market, By Drug Type
- Global Myocardial Ischemia Market, By End User
- Global Myocardial Ischemia Market, By Distribution Channel
- Global Myocardial Ischemia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Myocardial Ischemia Market, By Disease Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Stable Angina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Unstable Angina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Silent Myocardial Ischemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Vasospastic (Prinzmetal) Angina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Microvascular Ischemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Myocardial Ischemia Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Anti-Anginal Agents (e.g., nitroglycerin, isosorbide mononitrate)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antiplatelet Agents (e.g., aspirin, clopidogrel, ticagrelor)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Anticoagulants (e.g., heparin, enoxaparin, apixaban)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Beta-Blockers (e.g., metoprolol, atenolol, carvedilol)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- ACE Inhibitors (e.g., ramipril, lisinopril, enalapril)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Angiotensin II Receptor Blockers (e.g., losartan, valsartan, telmisartan)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Calcium Channel Blockers (e.g., amlodipine, diltiazem, verapamil)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Nitrates (e.g., nitroglycerin spray, isosorbide dinitrate)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Statins (e.g., atorvastatin, rosuvastatin, simvastatin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Late Sodium Current Inhibitors/Ranolazine (e.g., ranolazine)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Thrombolytics (e.g., alteplase, tenecteplase, streptokinase)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Myocardial Ischemia Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Myocardial Ischemia Market, By Drug Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Myocardial Ischemia Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cardiac Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Myocardial Ischemia Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Myocardial Ischemia Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck and Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
